Jan 13, 2025
Bristol Myers Squibb stands tall as the undisputed leader in the molecular glue arena, shaping the future of targeted therapies. With its groundbreaking advancements, the company has redefined the potential of molecular glues in oncology, offering innovative solutions that precisely degrade harmful proteins. Bristo...
Read More...
Jan 10, 2025
Molecular glues are a groundbreaking class of small molecules that are gaining significant attention in the field of drug discovery. These compounds offer a novel approach to modulating protein function, especially for challenging targets that have been difficult to address using traditional drug discovery methods....
Read More...
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Mar 06, 2026
BYSANTI Approval Positions Vanda to Compete in the Antipsychotic Market
Mar 02, 2026
Newsletter/Whitepaper